Active Ingredient(s): Alogliptin + Pioglitazone
FDA Approved: * January 25, 2013
Pharm Company: * TAKEDA PHARMS USA
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Oseni Overview

Alogliptin, sold under the brand names Nesina and Vipidia,[1][2]) is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class.[3] Alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination wi...

Read more Oseni Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Alogliptin

Recent Oseni Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Alogliptin + Pioglitazone
  • Tablet: 12.5mg + 15mg, 12.5mg + 30mg, 12.5mg + 45mg, 25mg + 15mg, 25mg + 30mg, 25mg + 45mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Oseni: (6 results)

Sorted by National Drug Code
  • 64764-121 Oseni 12.5/15 Oral Tablet by Takeda Pharmaceuticals America, Inc.
  • 64764-123 Oseni 12.5/30 Oral Tablet by Takeda Pharmaceuticals America, Inc.
  • 64764-124 Oseni 12.5/45 Oral Tablet by Takeda Pharmaceuticals America, Inc.
  • 64764-251 Oseni 25/15 Oral Tablet by Takeda Pharmaceuticals America, Inc.
  • 64764-253 Oseni 25/30 Oral Tablet by Takeda Pharmaceuticals America, Inc.
  • 64764-254 Oseni 25/45 Oral Tablet by Takeda Pharmaceuticals America, Inc.

Drugs with one or more similar ingredients: (13 results)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 23 April 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA